Retarding progression of chronic renal disease: the neglected issue of residual proteinuria - PubMed (original) (raw)
Clinical Trial
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria
Piero Ruggenenti et al. Kidney Int. 2003 Jun.
Free article
Abstract
Background: Findings that early changes in proteinuria independently predict long-term glomular filtration rate (GFR) decline (Delta GFR) would highlight proteinuria as a major determinant of progression in chronic renal disease.
Methods: We investigated whether percent changes (3 months vs. baseline) in proteinuria (adjusted for concomitant changes in GFR) and residual proteinuria at 3 months, predicted Delta GFR [over a median (IQ range) follow up of 31.3 (24.5 to 50.3) months] in 273 patients with proteinuric chronic nephropathies enrolled in the Ramipril Efficacy In Nephropathy (REIN) study.
Results: Short-term changes and residual proteinuria (r = -0.23, P = 0.0001 for both) significantly correlated with Delta GFR and, at multivariate analyses, independently predicted Delta GFR (beta = -0.23, P = 0.0002; beta = -0.21, P = 0.0004, respectively). For comparable levels of residual proteinuria, patients with greater short-term reduction had slower Delta GFR (-0.28 +/- 0.04 mL/min/1.73 m2/ vs. -0.53 +/- 0.07 mL/min/1.73 m2/month, P = 0.04). On ramipril and conventional treatment, specular short-term changes in proteinuria (-18.2 +/- 3.5% vs. 24.2 +/- 6.7%, P < 0.0001, respectively) were associated with significantly different Delta GFRs. However, similar changes in proteinuria resulted in a difference in Delta GFR (ramipril, 0.39 +/- 0.07 mL/min/1.73 m2/month; conventional therapy, 0.74 +/- 0.11 mL/min/1.73 m2/month; P < 0.01) that was sevenfold higher (0.35 vs. 0.05 mL/min/1.73 m2/month) in patients with basal proteinuria > or =3 g/24 hours as compared to those with basal proteinuria 1 to 3 g/24 hours (ramipril, 0.25 +/- 0.06 mL/min/1.73 m2/month; conventional therapy, 0.30 +/- 0.07 mL/min/1.73 m2/month; P = NS).
Conclusion: Regardless of blood pressure control and treatment randomization, short-term changes in proteinuria and residual proteinuria reliably predict long-term disease progression. Reducing proteinuria is renoprotective, particularly in nephrotic patients. As for arterial hypertension, proteinuria should be a specific target for renoprotective treatment.
Similar articles
- Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Ruggenenti P, et al. Kidney Int. 1998 May;53(5):1209-16. doi: 10.1046/j.1523-1755.1998.00874.x. Kidney Int. 1998. PMID: 9573535 Clinical Trial. - Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G. Ruggenenti P, et al. Kidney Int Suppl. 1997 Dec;63:S54-7. Kidney Int Suppl. 1997. PMID: 9407422 Clinical Trial. - Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.
Chiurchiu C, Remuzzi G, Ruggenenti P. Chiurchiu C, et al. J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S58-63. doi: 10.1681/asn.2004110968. J Am Soc Nephrol. 2005. PMID: 15938036 Review.
Cited by
- Caloric restriction reduces proteinuria in male rats with established nephropathy.
Sijbesma JWA, van Waarde A, Klooster A, Kion I, Slart RHJA, Lammertsma AA, Giacobbo BL, Boersma HH, Dierckx RAJO, van Goor H, Bakker SJL. Sijbesma JWA, et al. Physiol Rep. 2024 Mar;12(5):e15942. doi: 10.14814/phy2.15942. Physiol Rep. 2024. PMID: 38439743 Free PMC article. - Risk factor analysis for a rapid progression of chronic kidney disease.
Vestergaard AHS, Jensen SK, Heide-Jørgensen U, Frederiksen LE, Birn H, Jarbøl DE, Søndergaard J, Persson F, Thomsen RW, Christiansen CF. Vestergaard AHS, et al. Nephrol Dial Transplant. 2024 Jun 28;39(7):1150-1158. doi: 10.1093/ndt/gfad271. Nephrol Dial Transplant. 2024. PMID: 38168720 Free PMC article. - Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Cooper TE, Teng C, Tunnicliffe DJ, Cashmore BA, Strippoli GF. Cooper TE, et al. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3. Cochrane Database Syst Rev. 2023. PMID: 37466151 Free PMC article. Review. - Management of Hypertension in Fabry Disease.
Kim SH, Choi SJ. Kim SH, et al. Electrolyte Blood Press. 2023 Jun;21(1):8-17. doi: 10.5049/EBP.2023.21.1.8. Epub 2023 Jun 27. Electrolyte Blood Press. 2023. PMID: 37434805 Free PMC article. Review. - Short term outcome of patients attending a renal-immunology clinic in central India.
Atlani M, Kapoor NK, Joshi D, Sutar R, Sharma T, Joshi A. Atlani M, et al. J Postgrad Med. 2022 Apr-Jun;68(2):78-84. doi: 10.4103/jpgm.JPGM_1320_20. J Postgrad Med. 2022. PMID: 35259787 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous